본문 바로가기

Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
KOREAN JOURNAL OF INTERNAL MEDICINE35(2) · pp.429 · 2020
피인용
Web of Science 2Scopus 3KCI 1
FWCI (Scopus)
0
JCR IF
JCR 2019 2.751
ISSN
1226-3303

저자

  1. Kim, Taeyun제1저자Department of Internal Medicine, Kosin University Gospel Hospital, Busan;, Korea
  2. Choi, YunsukDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan;, Korea
  3. Lee, Je-HwanDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul;, Korea
  4. Park, SilviaDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul;, Korea
  5. Ahn, Jae-SookDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun;, Korea
  6. Moon, Joon-HoDepartment of Hematology, Kyungpook National University Hospital, Daegu;, Korea
  7. 신호진Department of Internal Medicine, Pusan National University Hospital, Busan;, Korea
  8. Lee, Won SikDepartment of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea
  9. Kim, DajungDepartment of Internal Medicine, Kosin University Gospel Hospital, Busan;, Korea
  10. Lee, Ho Sup교신저자Department of Internal Medicine, Kosin University Gospel Hospital, Busan;, Korea

초록

Background/Aims: Rabbit anti-thymocyte globulin (ATG) is usually incorporated in hematopoietic stem cell transplantation (HSCT) to reduce the incidence of graft-versus-host disease (GVHD). This study aimed to find optimal ATG doses in patients undergoing human leukocyte antigen (HLA)-mismatched allogeneic HSCT. Methods: We retrospectively collected medical records from 352 consecutive patients with acute myeloid leukemia (n = 214), acute lymphoblastic leukemia (n = 62), or myelodysplastic syndrome (n = 76) in eight centers of Korea between 2005 and 2015. All patients received busulfan-based conditioning without total body irradiation (TBI) and received stem cells from HLA-mismatched donors. Results: In the current study, 5-year overall survival rates of patients receiving low to medium doses of ATG (2.5 to 7.5 mg/kg) were higher than those receiving other doses of ATG (hazard ratio [HR], 0.528; 95% confidence interval [CI], 0.311 to 0.897; p = 0.018). The incidence rates of extensive chronic GVHD (ecGVHD) after administration of low to medium doses of ATG were lower than those after other doses of ATG (HR, 0.447; 95% CI, 0.224 ton 0.889; p = 0.022). Conclusions: The low to medium doses of ATG may be associated with improving survival outcomes and reducing incidence of ecGVHD without enhancing the chances of relapse in patients with acute leukemia or myelodysplastic syndrome undergoing non-TBI-based HLA-mismatched allogeneic HSCT.

키워드

Antithymocyte globulinGraft vs host diseaseSurvivalHuman leukocyte antigen mismatchAllogeneic hematopoietic stem cell transplantationANTITHYMOCYTE GLOBULINRANDOMIZED-TRIALDONORPROPHYLAXISPREVENTIONLEUKEMIAATGTHYMOGLOBULINDEPLETIONSTANDARD

식별자

Scopus EID
2-s2.0-85079219977
WoS UID
000518386700020
KCI
ART002563014